CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself. Innovation is at the heart of everything we do. It is reflected in our creation of state of the art plasma collection and manufacturing facilities, our investment in improving current therapies, finding new indications for existing therapies, and innovating new therapeutic products for unmet needs
Quote | CSL Ltd ADR (OTCMKTS:CSLLY)
Last: | $86.818 |
---|---|
Change Percent: | -0.12% |
Open: | $85.975 |
Close: | $86.918 |
High: | $87.03 |
Low: | $85.975 |
Volume: | 25,788 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | CSL Ltd ADR (OTCMKTS:CSLLY)
2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...
2024-03-28 05:42:57 ET Akebia Therapeutics ( NASDAQ: AKBA ) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients o...
Message Board Posts | CSL Ltd ADR (OTCMKTS:CSLLY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure Canada NewsWire ST. GALLEN, SWITZERLAND , March 19, 2024 /CNW/ -- CSL Vifor today a...
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season PR Newswire SUMMIT, N.J. , March 6, 2024 /PRNewswire/ -- CSL Seqirus, a glob...
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is based on pivotal Phase 3 PROTECT Study results European Commission dec...